Autres langues BeyondSpring Inc.

Actions

BYSI

KYG108301006

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 03/05/2024			Varia. 5j.	Varia. 1 janv.
2,25 ^USD	+4,16 %		+5,63 %	+150,00 %

25/03	BeyondSpring annonce le dosage du premier patient dans l'essai de phase 2 du traitement combiné du cancer du poumon	MT
25/03	BeyondSpring annonce que le premier patient a reçu le dosage de Pembrolizumab, Plinabulin plus Etoposide/Platine dans une étude de phase 2 initiée par un investigateur sur le cancer du poumon à petites cellules au stade extensif de première ligne.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics	03/05
BeyondSpring Files 2023 Annual Report on Form 20-F	29/04
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results	29/04
North American Morning Briefing : Investors Brace -2-	29/04
North American Morning Briefing : Stock Futures -2-	22/04
North American Morning Briefing : Stock Futures -2-	15/04
BeyondSpring Says First Patient Dosed in Phase 2 Trial of Lung Cancer Combination Treatment	25/03
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer	25/03
Beyondspring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in A Phase 2 Investigator-Initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer	25/03
BeyondSpring Inc. Announces Executive Changes	18/03
Top Premarket Decliners	06/03
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements	26/02
BeyondSpring Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	02/02
BeyondSpring Receives Non-Compliance Notice From Nasdaq	10/01
BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K	10/01
BeyondSpring Receives Notification From Nasdaq for Breaching Minimum Bid Price Requirements	19/12
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements	18/12
BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors	07/11
BeyondSpring Inc. Announces New Data That Translates Preclinical Proof-Of-Concept to Clinical Evidence of Plinabulin?s Immunomodulating Activity	07/11
BEYONDSPRING AND PROFESSOR K. EISENMANN OF THE UNIVERSITY OF TOLEDO COLLEGE OF MEDICINE PRESENT POSTER HIGHLIGHTING PLINABULIN'S ANTI-CANCER EFFICACY IN PRIMARY AND RECURRENT GLIOBLASTOMA PATIENT DERIVED INVASIVE NEUROSPHERE MODELS	01/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues BeyondSpring Inc.

Actions

BYSI

KYG108301006

Autres langues

Filtres